Cartesian Therapeutics logo

Cartesian Therapeutics

RNAC | NASDAQ
Chart Builder DCF Calculator
$6.08
-$0.27 (-4.25%)
At close: Nov 16, 2026, 4:00 PM ET
$6.19
+$0.11 (+1.81%)
After-hours: Nov 16, 2026, 7:32 PM ET
-4.25%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
43
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #446/1021 (Top 44%)

Key Statistics

Market Data

Market Cap $185.46M
1D Range
6.06 6.44
52W Range
5.84 10.59

Valuation (TTM)

PE -1.26
PB -1.42
EV/EBITDA -1.00

Valuation (NTM)

Forward PE N/A
Forward PEG 0.18
Price Target $20.50
Loading financial charts...

Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an au...

Sector Healthcare
Industry Biotechnology
Employees 75
IPO Date Jun 22, 2016
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.38
Beat +62.38%
REV
$250K
Beat +56.25%
Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$20.50
Upside
+237.17%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.